Senti Biosciences is trading 10.34% lower at $0.20 as broad market risk-off sentiment weighs on shares. - No fresh company-specific catalyst was identified for October 22. - Earlier disclosures covered the latest shareholder approvals related to the merger and proposed reverse split. - Reuters reported that rising oil prices and renewed concerns about technology spending were pressuring markets; major indices in the supplied market context were also lower.